DV
Dividend Vision

CBIO — Crescent Biopharma, Inc.

Crescent Biopharma, Inc. (CBIO)

Total return is -97.9% over the past 12.6 years, 518.3 points behind SPY at 420.4%. Its deepest 1-year drawdown was 46.4%.

CBIO is an equity fund focused on the biopharmaceutical sector, holding individual biotech company stocks. The fund does not currently have a distribution rate, expense ratio, or published asset under management figures available. This fund structure appeals primarily to growth-oriented investors seeking exposure to biotechnology companies rather than those prioritizing dividend income.

CBIO key facts

Asset type
Stock
Asset class
Equity
Inception date
01/10/2014
Last close
$17.14
Market cap
$526,126,848
Average volume
229861.0
Ex-dividend date
01/13/2023
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.88